#USA #New York #Gross Law Firm #Nektar Therapeutics #NKTR

Deadline Alert: Nektar Therapeutics Shareholders

As a shareholder of Nektar Therapeutics (NASDAQ: NKTR), it's crucial to be aware of your rights and potential claims against the company. The Gross Law Firm has recently issued an important notice highlighting the upcoming deadline for shareholders to join a class action lawsuit related to misleading statements made by Nektar Therapeutics during a specified class period.

Key Dates and Details

The deadline for investors to register as potential lead plaintiffs in this case is May 5, 2026. If you purchased shares of NKTR between February 26, 2025, and December 15, 2025, you may qualify to participate in this class action.

The allegations suggest that during this time frame, Nektar Therapeutics made false or misleading statements. Specifically, it has been claimed that:

• - The REZOLVE-AA trial enrollment did not adhere to standard protocols.
• - This mismanagement may greatly affect the trial's outcomes.
• - Consequently, the anticipated results and overall integrity of the trial were inaccurately represented in public statements.

These factors led to significant inflation of NKTR stock prices, resulting in unjust losses for the investors when the truth was revealed.

Why Should Shareholders Act?

Taking part in the class action does not require you to become a lead plaintiff; however, signing up will provide you with ongoing updates about the case through monitoring software. Registration holds no cost or obligation for shareholders, making it a proactive step for those who accrued losses tied to Nektar.

Joining this lawsuit gives shareholders a collective voice and a better chance for recovery following any misrepresentation or negligence by the company. Additionally, participating in this lawsuit aligns with the Gross Law Firm’s commitment to ensuring that corporate entities uphold ethical standards.

How to Register

To register, investors should visit the Gross Law Firm's dedicated submission page for this case:
Registration Link
This registration process only requires basic information regarding your purchases of NKTR shares.

About Gross Law Firm

The Gross Law Firm is recognized nationally for advocating investors' rights in class-action lawsuits. Their mission revolves around protecting the interests of those who have suffered from corporate deceit or failure to disclose important information. With a strong track record, the firm diligently fights for fair recovery and accountability from the companies that fail to maintain transparency with their stakeholders.

If you find yourself affected by recent developments at Nektar Therapeutics or wish to ensure your interests as a shareholder are protected, consider taking action promptly.

For any inquiries about your case or for further assistance, you can reach out directly to:

• - The Gross Law Firm

Address: 15 West 38th Street, 12th Floor, New York, NY 10018
Phone: (646) 453-8903
Email: [email protected]


Remember, the deadline is approaching fast. Ensure your participation for a collective pursuit of justice and accountability against misinformation in the financial market.